Subscribe
shutterstock_1392543575_pavel_kapysh
Pavel Kapysh / Shutterstock.com
3 January 2020AmericasSarah Morgan

Adamas settles Gocovri clash with Sandoz

California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.
Americas
AbbVie secures another Humira settlement
12 October 2018   AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.
Americas
AbbVie secures another Humira settlement
12 October 2018   AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.

More on this story

Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.
Americas
AbbVie secures another Humira settlement
12 October 2018   AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler